Find your next paid study

Medical University of ViennaNCT01356290

~$10 – $6,250

Selected Advanced Solid TumorsColorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+4 more

A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors

This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors. SKL35502 is …

SK Life Science, Inc.NCT07812805

Diffuse Midline Glioma or Diffuse Intrinsic Pontine GliomaHigh Grade GliomasMedulloblastoma Recurrent+3 more

A Safety and Feasibility Study of NeuroNavigation-Guided Low Intensity Focused Ultrasound With Microbubbles to Enhance Nivolumab Delivery for the Treatment of Relapsed and Progressive Diffuse Midline Glioma and Other High Grade Brain Tumors

This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for progressive and relapsed diffuse midline glioma (DMG) and…

Children's National Research InstituteNCT07664176

~$10 – $5,625

CancerAdvanced CancerLocally Advanced Carcinoma+8 more

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various …

Angiex, Inc.NCT06440005

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M0324, a Bispecific (MUC-1 x CD40) Antibody as Monotherapy, in Combination With Pembrolizumab, and in Combination With Chemotherapy, in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining i…

Advanced Solid Tumor

EMD Serono Research & Development Institute, Inc.NCT07166601

Advanced Solid TumorPDACHNSCC

First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conj…

~$10 – $7,500

Adcendo ApSNCT06597721

A Phase 1/2a, Open-Label Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA53-OS, an MDM2 Inhibitor, in Patients With Locally Advanced or Metastatic p53 Wild-Type Solid Tumors

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors. The study i…

Solid Tumor

Lamassu Bio IncNCT06578624

Phase 2

A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone

The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work mo…

Brain CancerBrain MetastasesMelanoma+13 more

Brigham and Women's HospitalNCT04899908

~$10 – $6,250

A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity …

Advanced Solid Tumor

~$10 – $7,500

BioNTech SENCT06750185

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

Iambic Therapeutics, IncNCT06253871

First-in-human, Open-label, Phase 1 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Select Advanced Malignant Solid Tumors

The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has m…

Advanced Solid Tumors

A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. …

Malignant Solid Tumors